title: Effects of the luteinizing hormone-releasing hormone agonist leuprolide on lipoproteins, fibrinogen and plasminogen activator inhibitor in patients with benign prostatic hyperplasia.
abstract: The impact of chronic administration of the luteinizing hormone-releasing hormone agonist leuprolide depot on cardiovascular risk factors was investigated in a controlled double-blind study comprising 50 evaluable patients with benign prostatic hyperplasia. In the 26 patients receiving leuprolide the mean total cholesterol level increased by 10.6%, high density lipoprotein cholesterol by 8.2% and triglycerides by 26.9% (p = 0.003, 0.052 and 0.050, respectively). Low density lipoprotein cholesterol levels were unchanged. Apolipoprotein A1 increased by 13.2% (p = 0.001), while apolipoprotein B, fibrinogen, thrombocytes and plasminogen activator inhibitor were unchanged. Hemoglobin decreased by 1.2 gm./100 ml. without a concomitant decrease in serum erythropoietin concentration. These changes act in different directions with regard to cardiovascular risk and the overall effect is difficult to assess.
authors.affiliation: Department of Surgery (Division of Urology), Ullevaal University Hospital, Oslo, Norway.
authors.forename: L M
authors.initials: LM
authors.lastname: Eri
authors.forename: P
authors.initials: P
authors.lastname: Urdal
authors.forename: A G
authors.initials: AG
authors.lastname: Bechensteen
mesh_terms: D000368:Aged; D016632:Apolipoprotein A-I / Q000097:blood; D001055:Apolipoproteins B / Q000097:blood; D001792:Blood Platelets / Q000187:drug effects / Q000473:pathology; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D004311:Double-Blind Method; D004921:Erythropoietin / Q000097:blood; D004958:Estradiol / Q000097:blood; D005340:Fibrinogen / Q000032:analysis*; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D016729:Leuprolide / Q000494:pharmacology* / Q000627:therapeutic use; D008074:Lipoproteins / Q000097:blood*; D008297:Male; D010919:Placebos; D017395:Plasminogen Activator Inhibitor 1 / Q000097:blood*; D011470:Prostatic Hyperplasia / Q000097:blood* / Q000188:drug therapy; D013739:Testosterone / Q000097:blood; D014280:Triglycerides / Q000097:blood
chemical_list: D016632:Apolipoprotein A-I; D001055:Apolipoproteins B; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D006454:Hemoglobins; D008074:Lipoproteins; D010919:Placebos; D017395:Plasminogen Activator Inhibitor 1; D014280:Triglycerides; D004921:Erythropoietin; D013739:Testosterone; D004958:Estradiol; D005340:Fibrinogen; D016729:Leuprolide